1. Home
  2. CTNM vs AMBI Comparison

CTNM vs AMBI Comparison

Compare CTNM & AMBI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CTNM
  • AMBI
  • Stock Information
  • Founded
  • CTNM 2009
  • AMBI 1995
  • Country
  • CTNM United States
  • AMBI Brazil
  • Employees
  • CTNM N/A
  • AMBI N/A
  • Industry
  • CTNM
  • AMBI Environmental Services
  • Sector
  • CTNM
  • AMBI Industrials
  • Exchange
  • CTNM Nasdaq
  • AMBI Nasdaq
  • Market Cap
  • CTNM 248.7M
  • AMBI 265.0M
  • IPO Year
  • CTNM 2024
  • AMBI N/A
  • Fundamental
  • Price
  • CTNM $12.16
  • AMBI N/A
  • Analyst Decision
  • CTNM Strong Buy
  • AMBI
  • Analyst Count
  • CTNM 5
  • AMBI 0
  • Target Price
  • CTNM $22.20
  • AMBI N/A
  • AVG Volume (30 Days)
  • CTNM 194.4K
  • AMBI 742.3K
  • Earning Date
  • CTNM 11-05-2025
  • AMBI 08-12-2014
  • Dividend Yield
  • CTNM N/A
  • AMBI N/A
  • EPS Growth
  • CTNM N/A
  • AMBI N/A
  • EPS
  • CTNM N/A
  • AMBI N/A
  • Revenue
  • CTNM N/A
  • AMBI $525,221,427.00
  • Revenue This Year
  • CTNM N/A
  • AMBI N/A
  • Revenue Next Year
  • CTNM N/A
  • AMBI N/A
  • P/E Ratio
  • CTNM N/A
  • AMBI N/A
  • Revenue Growth
  • CTNM N/A
  • AMBI 25.42
  • 52 Week Low
  • CTNM $3.35
  • AMBI $0.72
  • 52 Week High
  • CTNM $20.24
  • AMBI $8.20
  • Technical
  • Relative Strength Index (RSI)
  • CTNM 56.27
  • AMBI 14.89
  • Support Level
  • CTNM $10.65
  • AMBI $1.06
  • Resistance Level
  • CTNM $12.14
  • AMBI $1.38
  • Average True Range (ATR)
  • CTNM 0.92
  • AMBI 0.41
  • MACD
  • CTNM -0.21
  • AMBI -0.37
  • Stochastic Oscillator
  • CTNM 34.98
  • AMBI 2.28

About CTNM Contineum Therapeutics Inc. Class A Common Stock

Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.

About AMBI Ambipar Emergency Response

Ambipar Emergency Response is a environmental, emergency response and industrial field service provider in Brazil with presence in 16 countries in Latin America, North America, Europe, Africa and Antarctica. The company provides customers with a full suite of environmental services organized around prevention, training and emergency response on all transportation modes. The portfolio includes a broad variety of services such as environmental remediation, industrial field services, industrial cleaning of chemical and non-chemical products and of hazardous and non-hazardous waste, consulting services focused on accident prevention and environmental licensing.

Share on Social Networks: